Results 61 to 70 of about 1,993 (117)
Journal of Applied Clinical Medical Physics, Volume 27, Issue 7, July 2026.Abstract Background Terbium‐161 (Tb‐161) emits gamma rays and beta radiation, enabling both therapeutic and imaging applications. However, the multiple gamma emissions of 161Tb can affect image quality by increasing the scattering rate during SPECT imaging.
Melek Can +3 more
wiley +1 more source
EJNMMI Research, 2018 Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation.
Daphne Merel Valerie Huizing +3 more
doaj +1 more source
Advanced Science, Volume 13, Issue 39, 13 July 2026.Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang +11 more
wiley +1 more source
Peptide receptor radionuclide therapy (PRRT) special issue
DATA AVAILABILITY STATEMENT : Data sharing is not applicable to this article as no new data were created or analyzed in this study.Peptide receptor radionuclide therapy (PRRT), a form of radioligand therapy (RLT), is a well-established treatment in well ...
Navalkissoor, Shaunak, Millar, Robert P.
core +1 more source
Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome
Clinical Case Reports, Volume 14, Issue 7, July 2026.ABSTRACT Lynch syndrome (LS), a well‐known cancer risk syndrome, is caused by deleterious germline mutations in the mismatch repair genes. LS predispose patients to various types of cancers including colon adenocarcinoma. We discuss the case of a woman with LS who also developed a non‐functioning pancreatic neuroendocrine tumor (P‐NET) following ...
Fateme Salemi +5 more
wiley +1 more source
Peptide Receptor Radionuclide Therapy (PRRT)
, 2015 Neuroendocrine tumors are generally slow growing and are frequently discovered when metastatic spread has occurred. This leaves room for multiple treatments, individualized through a multidisciplinary approach that considers tumor type, extension, and ...
Bodei, Lisa +3 more
core +1 more source
IJU Case Reports, Volume 9, Issue 4, July 2026.ABSTRACT Introduction 68Ga‐DOTATOC positron emission tomography/computed tomography (PET/CT) targets somatostatin receptors (SSTRs) and is an established molecular imaging modality for neuroendocrine tumors (NETs). Although SSTR expression has been reported in renal cell carcinoma (RCC), its clinical utility remains unclear. Case Presentation A 76‐year‐
Yuta Mine +9 more
wiley +1 more source
, 2020 Peptide Receptor Radionuclide Therapy (PRRT) is a complex treatment modality for patients and their carers to navigate alone. As PRRT is a tertiary/quaternary service, patients are often referred from smaller institutions with potential for confusion due
Corsini, Nadia +6 more
core +1 more source
The lowest observed value per haematological parameter and CTCAE grade during PRRT course.
, 2021 The lowest observed value per haematological parameter and CTCAE grade during PRRT course.
Daphne M. V. de Vries–Huizing (11725367) +8 more
core +1 more source
Journal of Neuroendocrinology, Volume 38, Issue 7, July 2026.Abstract Introduction: VIPoma is an extremely rare functioning pancreatic neuroendocrine tumor. Therefore, data regarding treatment and outcome are very limited. Aim (s): This multicenter study aimed to analyze clinical characteristics, real‐world management, and outcomes of patients with VIPoma.
Detlef K. Bartsch +15 more
wiley +1 more source